Showing: 1 - 8 of 8 RESULTS

SEngine Precision Medicine to Present at Society of Functional Precision Medicine Virtual …

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) — SEnginePrecision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor organoids, today announced that Chief Medical Officer Astrid L. Margossian, MD, PhD, will present at the Society for Functional Precision Medicine (SFPM) Virtual Monthly Seminar on October 14th at 11:30 am ET.

Dr. Margossian is leading SEngine’s clinical validation initiatives for the PARIS® Test, a CLIA certified cancer organoid based drug sensitivity test for all solid tumors. The presentation is entitled, “Predictive Clinical Value of a CLIA-Approved Organoid Based Drug Sensitivity Test,” and will highlight the data on the PARIS® Test, recently presented at the ASCO 2020 and ACCR 2020 annual meetings, inclusive of organoids sensitivity results, showing clinical correlation with genomics and previous clinical treatments. Registration for the live event is available for free at https://www.sfpm.io/seminars.php.

SFPM’s virtual monthly seminar brings together distinguished guest speakers and through interactive panel discussions and Q&A sessions focuses on these key topics:

  • Demonstrating the clinical utility of functional precision medicine testing
  • Implementing functional testing in precision medicine clinical trials
  • Accelerating the application of functional testing
  • Addressing stakeholder, educational and investment challenges for functional precision medicine

About PARIS® Test
The CLIA certified PARIS® Test is based on the capability to propagate patient-specific cancer tissue as organoids ex vivo and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where the path is not clear, such as many metastatic and recurrent cancers, the PARIS test provides crucial information to the treating physicians to match the right drug to the right patient.

About SEngine Precision Medicine
SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

Contact:
Stephanie Carrington
stephanie.carrington@westwicke.com
646-277-1282

Source Article

Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (racemetyrosine) late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in prostate, breast and hematological cancers.

Event: Jefferies Virtual Global Healthcare Conference
Place: Waldorf Hilton, London
Presentation Date: November 17-19, 2020
Format: One-on-one sessions

The presentation will be accessible on the events page under the investor relations section of Tyme Technologies’ website at www.tymeinc.com.

About SM-88

SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. Learn more.

About TYME-18

TYME-18 is composed of a proprietary surfactant delivery agent with a specific sulfonic acid component. It is designed for intra-tumoral administration of difficult to treat tumors and leverages the acidic tumor microenvironment and signaling pathways to kill cancer cells. TYME-18 is distinct in composition, but like SM-88, aims to leverage susceptibilities of a cancer that are related to its altered metabolism. Initial preclinical data for TYME-18 in animal tumor models demonstrate rapid and complete tumor regression, with no reported local or systemic toxicities. TYME-18 continues to be studied as a potential therapy for difficult to treat tumors that may not be eligible for surgical or other interventions. Learn more.

About TYME-19

TYME-19 is a potent, well characterized synthetic antiviral bile acid that is being evaluated as a potential oral therapy for COVID-19. In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity in treated cells. COVID-19 hijacks a cell’s ability to make proteins and lipids and divert these processes to make viral proteins and lipids in order to reproduce. COVID-19 accomplishes this by inducing stress in the endoplasmic reticulum (ER), where cells process proteins, which enables the virus to remodel protein and lipid synthesis. In preclinical testing, TYME-19 has been shown to counteract these effects, preventing viral replication, by reducing ER stress. TYME-19 is believed to physically degrade viruses by solubilizing the protective lipid layer and other structural components, which prevent a virus from binding to and infecting a cell.

About TYME-88-Panc Pivotal Trial

The TYME-88-Panc pivotal trial applies the latest advances in the field of cancer metabolism by evaluating the efficacy and safety of an oral investigational compound that targets the metabolic mechanisms of the

Progenity to Present Precision Medicine Abstracts at American College of Gastroenterology (ACG) …

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

October 9, 2020 GMT

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, is pleased to announce that two abstracts related to Progenity’s ingestible technologies for the diagnosis and treatment of gastrointestinal disorders have been accepted for presentation at American College of Gastroenterology (ACG) virtual annual meeting set to take place October 23-28, 2020. Progenity will be presenting one oral presentation and one poster presentation.

The accepted abstract titles and study findings will be a part of the event’s on-demand sessions and virtual e-poster hall, which are embargoed until October 26 at 8:00 a.m., EST, to coincide with the start of the ACG 2020 Virtual Annual Scientific Meeting. More information about these abstracts will be made available on the Progenity website following the conference.

About Progenity
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at  www.progenity.com.

Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886

Media Contact:
Kate Blom-Lowery
CG Life
kblomlowery@cglife.com
(619)743-7294

Source Article

Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will be presenting at the Alliance for Regenerative Medicine’s (ARM) virtual Cell and Gene Meeting on the Mesa, taking place October 12-16, 2020. Michael Redman, Executive Vice President and Chief Operating Officer of Genprex, will lead the company’s presentation.

The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day. The Cell and Gene Meeting on the Mesa is the sector’s foremost annual conference, bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.

For more information on the conference, or to register, please visit https://www.meetingonthemesa.com.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute

Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting

Optometry and ophthalmology doctors to present latest analyses and updates from studies of its MAP therapeutics for mydriasis, pediatric myopia and presbyopia

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Drs. Siddarth Rathi and April Jasper will present the latest analyses and updates from the company’s clinical studies at the American Academy of Optometry Academy 2020 At Home Con.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201005005232/en/

On Wednesday, October 7, April Jasper, OD, medical monitor for the company’s CHAPERONE study and member of the Eyenovia Scientific Advisory Board, will provide pre-recorded updates on the CHAPERONE (evaluation of low-dose atropine for the reduction of pediatric myopia progression) and the VISION (evaluation of low-dose pilocarpine for improvement in near vision) clinical trials. Dr. Jasper will also provide an update on the company’s upcoming Mydcombi (low-dose tropicamide and phenylephrine fixed combination for pupil dilation) NDA filing with the U.S. Food and Drug Administration (FDA).

On Thursday, October 8 at 6 p.m. EDT, Siddarth Rathi, MD, of The Eye Institute of West Florida and medical monitor for the MIST 1 and MIST 2 studies, will present additional analyses of data from the MIST 1 and MIST 2 studies of Eyenovia’s proprietary first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (pupil dilation). Clinical results will cover Pupil Dilation Speed with MAP™ Fixed Combination (FC) Tropicamide 1% Phenylephrine 2.5% (TR-PH)-Ophthalmic Solution.

About Eyenovia

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, please visit www.eyenovia.com.

About MicroPine for Progressive Myopia

MicroPine (atropine ophthalmic solution) is being evaluated in the CHAPERONE Phase 3 clinical study for reduction in pediatric myopia progression. Progressive myopia is estimated to affect close to 5 million children in the United States who suffer from uncontrolled axial elongation of the sclera leading to increasing levels of myopia and in some cases major pathologic changes such as retinal atrophy, myopic maculopathy, retinal detachment, posterior subcapsular cataract, glaucoma and visual impairment. MicroPine has been developed for comfort, hygiene and ease-of-use in children. Microdose administration of MicroPine is anticipated to result in low systemic and ocular drug exposure. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology indicates Level 1 (highest) evidence of efficacy for the role of low dose atropine for progressive myopia (Ophthalmology 2017;124:1857-1866; Ophthalmology 2016; 123(2) 391:399).

Feasibility Dose-finding Atropine Studies: ATOM 1; ATOM 2; LAMP (Independent Collaborative Group Trials)

About MicroLine for Presbyopia

MicroLine (pilocarpine ophthalmic solution) is a pharmacologic treatment for presbyopia which will be evaluated in the VISION 1 and VISION 2 Phase 3 clinical studies. Presbyopia is the non-preventable, age-related hardening of the natural lens, which causes a gradual loss of the eye’s ability to accommodate or focus on nearby

Insilico Medicine to present at Leveraging Intelligent Tech for Drug Development

IMAGE

IMAGE: Leveraging intelligent tech for drug development.
view more 

Credit: Insilico Medicine

Wednesday, September 30, 2020 – Insilico Medicine, a global leader in artificial intelligence for drug discovery and development, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Live Leveraging Intelligent Tech for Drug Development Forum on September 30, 2020.

AI, automation and data integration are condensing the timeline from discovery to development and solving biological problems. On September 30th, leaders from biotech and pharma will discuss specific examples of how these technological advancements are reshaping the drug development landscape.

While technology continues to revolutionize biotech, pharmaceutical companies are investing heavily in modernizing internally to embrace and embed these innovations throughout their organizational structure and culture. On the clinical trial front, not only are sponsors pressed to have remote and decentralized designs for their trial models due to the ongoing COVID19 pandemic, but regulators have openly expressed their willingness to consider creative new ideas for trial design, including wearable technology for remote data capture. Meanwhile in the workforce, competition is fierce to recruit and maintain the best talent and to understand how the role of the scientist is evolving to embrace the future of tech-enabled biopharma.

“We are thrilled to have CEO Alex Zhavoronkov address stakeholders at the upcoming digital forum on Leveraging Intelligent Tech for Drug Development on September 30th, hosted by Unite Life Sciences. Insilco Medicine’s work in the use of AI in drug discovery for Sars-CoV-2 and the ongoing COVID19 Global Pandemic offers remarkable insight to participants in the forum, which convenes senior decision makers, investors, and innovators in pharma, biotech and venture capital to examine real-case scenarios for accelerating drug discovery and modernizing clinical trials with data & automation. Unite Life Sciences is the dedicated life science division of IQPC US. Their digital content & forums provide a platform to drive stakeholder engagement, collaboration, and transformational change in biopharma.” said Nicole Hayes, Managing Director, Unite Life Sciences.

“I am very happy to present at Leveraging Intelligent Tech for Drug Development – a great event to gain insight on how industry can successfully align innovation in science, design, regulatory process and patient-centricity.” said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine.

###

For further information, images or interviews, please contact: ai@insilico.com.

About Insilico Medicine


Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

S

Effects Of Greed In The World In the present day?

The dentist is a very important doctor in the lives of people. One of the predominant reasons for opposition to universal healthcare is the argument of the effectiveness of free markets at offering higher outcomes and value controls. 8. Root Canal Remedy – or often known as endodontics, is a dental therapy that focuses on the middle of the tooth.

That is to make sure there aren’t any lawsuits), Eliminate COBRA & MediCare & Medicaid (these authorities applications are very VERY advanced – in some circumstances worse than the tax code – which is why administrative costs at hospitals and insurance corporations are so high, which immediately influences your premiums), as soon as all of that is finished, and we see billions of dollars and pink tape saved and removed, I gaurantee you will note huge enchancment in healthcare, and extra individuals who can afford coverage.

It causes cold sweats, nervousness and severe anxiety.” A survey by Submit Workplace Telecom in 2010 had revealed that the stress levels evoked by the nervousness of being with no cell phone equated to the stress of visiting a dentist, shifting houses and even getting married.

First, your lips and gums are coated so that only your teeth are uncovered to the treatment. Healthcare costs now aren’t sustainable. Aspirating materials are the third kind of dental tools and provides that your dentist used to work in your tooth with. This author lists quite a few countries with so known as efficient Nationwide Healthcare, when actually these applications are falling because of rising costs and substantial decreases in the high quality care.

I’ve not skilled sadistic conduct, however I’ve had my teethed drilled with the tiniest fillings anyone has ever seen, to pay for my dentists wants. Colgate Total is the only toothpaste that prevents my gums from bleeding. Your dentist ought to have the ability to answer all the questions that you’ve from them, from simple tasks to taking good care of your enamel, to explaining intimately every step of a more sophisticated procedure.…

Key Points Of Present Legislative Necessities And Codes Of Observe

The wants of a dental doctor who will cater any dental problems of every particular person or people below one roof must be thought-about vital. They supply membership right into a service partnership which connects sufferers with dental care providers at deeply discounted rates. I’ll be taking a closer have a look at completely different elements of the healthcare debate over the course of the next few weeks.

• The gums feel painfully. Throughout this visit the dentist will re-examine your enamel and gums, check for any decay or cavity, clean your tooth, and discuss tricks to maintain your oral hygiene and emphasize on preventive dentistry. Nationwide security, common healthcare, social providers for aged and disabled, training, infrastructure, and many others.

This Hub presents questions and solutions that might be of interest to anyone considering pursuing either a second or a first career within the professional subject of dentistry. Right now dentistry has evolved tremendously and even for these individuals who have lost their teeth, many affordable remedy choices are available to remain healthy and regain their stunning smile.

The home invoice and the senate invoice each embrace a number of provisions concerning mental well being care, together with legislation that would require insurance coverage corporations to deal with psychological well being issues as fairly as other medical concerns, which reform is also making an attempt to boost the requirements of.

There are numerous dental workplaces that use emails to remind sufferers of appointments and also to inform them of openings within the dentists schedule after they may schedule an appointment. I additionally think it is sensible that this dentist has solely toys or sugar free gum within the machines-it helps what the dentist is attempting to do (while sugared sweet would counter the dentist’s recommendation on consuming healthfully).…